GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nanexa AB (OSTO:NANEXA) » Definitions » Debt-to-Revenue

Nanexa AB (OSTO:NANEXA) Debt-to-Revenue : 0.06 (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Nanexa AB Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Nanexa AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.00 Mil. Nanexa AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr1.83 Mil. Nanexa AB's annualized Revenue for the quarter that ended in Mar. 2024 was kr31.02 Mil. Nanexa AB's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.06.


Nanexa AB Debt-to-Revenue Historical Data

The historical data trend for Nanexa AB's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanexa AB Debt-to-Revenue Chart

Nanexa AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.02 1.64 1.61 2.19 0.14

Nanexa AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.11 0.10 0.09 0.15 0.06

Competitive Comparison of Nanexa AB's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Nanexa AB's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nanexa AB's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nanexa AB's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Nanexa AB's Debt-to-Revenue falls into.



Nanexa AB Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Nanexa AB's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1.945 + 2.087) / 29.327
=0.14

Nanexa AB's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0 + 1.831) / 31.016
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


Nanexa AB Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Nanexa AB's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Nanexa AB (OSTO:NANEXA) Business Description

Traded in Other Exchanges
N/A
Address
Virdings Alle 32B, Uppsala, SWE, 75450
Nanexa AB is a pharmaceutical company developing injectable drug products based on the proprietary and innovative drug delivery system PharmaShell - the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. The company develops its own products and also has collaboration agreements with several pharma companies, among others AstraZeneca.

Nanexa AB (OSTO:NANEXA) Headlines

No Headlines